Moderna, Inc Equity-NMS: MRNA

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :	$49.81
Open :	$50.24
Today's high :	$55.2
Today's low :	$50.05
52W low :	$22.28
52W high :	$55.2
1Y :	29.74%
5Y :	-62.57%
EPS(TTM): :	-8.06
Shares O/S :	390.73 M
Market cap :	20.27 B

What is the share price of Moderna, Inc today?

Moderna, Inc (MRNA) share price as of January 23, 2026, is $51.87. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Moderna, Inc?

Yes, Indian Investors can invest in the Moderna, Inc (MRNA) Share by opening an international trading account with Angel One.

How can I purchase Moderna, Inc shares in India?

Purchasing Moderna, Inc (MRNA) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Moderna, Inc (MRNA) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Moderna, Inc?

Yes, you can purchase fractional shares of Moderna, Inc (MRNA) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Moderna, Inc?

The market capitalization of Moderna, Inc on January 23, 2026, is $20.27 B.

In which sector Moderna, Inc belongs?

Moderna, Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Moderna, Inc stocks?

In order to invest in Moderna, Inc (MRNA) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).